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Abstract
Hemostasis in neurosurgery has evolved significantly over the past few decades. 
New advances in hemostatic agents, some developed specifically with neurosurgical 
applications in mind, allowed for more effective control of difficult intraoperative 
bleeding. These agents vary in the mechanism of action and each may be indicated in 
different and often highly specific situations. Here we present a review of the most 
commonly used hemostatic agents, their mechanism of action and their indications. 
Focus is placed on key aspects and considerations regarding the use biosurgical mate-
rials in neurosurgery, with emphasis on clinical appropriateness and patient safety.
Keywords: biosurgery, biosurgical hemostat, biosurgical materials, hemostasis, 
neurosurgery, surgical bleeding
1. Introduction
The popularization of general anesthesia by William Morton in the 1840’s and 
the concept of antisepsis introduced by Joseph Lister would lead to a paradigm shift 
and the emergence of modern surgery [1, 2]. The mastery of surgery was no longer 
associated with speed or flamboyance, but instead focused on meticulous dissec-
tion, careful handling of tissues, hemostasis, and correct approximation of tissue 
planes to promote adequate healing. Among operative specialties, this transition 
from “art” to “science” of surgery was most profound in the neurosurgical field, 
enabling rapid advances to occur.
Early in the evolution of modern surgery, the issue of hemostatic control became 
prominent, as the heavily vascularized central nervous system and its propensity 
to bleed resulted in limitations of procedures and posed significant challenges 
[3–5]. Surgical ligation was utilized sparingly for fear of vessel rupture or vascular 
occlusion that may compromise entire vascular distributions. The instruments and 
techniques in neurosurgical armamentarium therefore relied predominately on 
application of pressure with gauze to combat bleeding [3, 6]. As a result, a search 
and incorporation of novel alternatives in hemostatic techniques would effectively 
lead to the development of modern neurosurgery as represented by Horsley’s use of 
bone wax and other pioneering hemostatic maneuvers [7, 8] and the introduction of 
electrosurgery by Cushing and Bovie in the 1920’s [9, 10]. Later in the revolutionary 
era of neurosurgery, biosurgical materials were introduced [6, 11].
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2. Neurosurgical biosurgery
In its broadest sense, the term biosurgery relates to the utilization of biomaterials 
that are defined as systemically and pharmacologically inert substances designed for 
implementation within or incorporation with living systems [12–14]. In the context of 
the current chapter, biosurgical materials (BSMs) are defined as biomaterials that are 
intended as adjuncts in attaining surgical hemostasis [15, 16]. The gradual development 
of hemostatic techniques has greatly impacted not only the field of neurosurgery, but 
all of surgery. The application of biosurgical agents first developed in the neurosurgical 
theater proved immensely valuable across virtually all surgical applications.
One of the earliest neurosurgical applications of biosurgical hemostats involved 
the control of bleeding in inaccessible areas with difficult tissue topography and in 
situations where use of electrocautery, sutures, or clips may simply not be feasible 
[4, 13, 17]. This chapter will review the categories, mechanism of action, efficacy, 
advantages, disadvantages, and complications of the various biological materials 
currently available for hemostasis in neurosurgery.
3. Classification
The abundance of biosurgical materials available for use requires a system of 
categorization. These agents can be divided into specific categories based on their 
mechanism of action, including passive or active hemostatics, flowable agents, and 
sealants [18–20]. Passive or mechanical agents act through contact with the site of 
bleeding to promote platelet aggregation [21, 22]. They form a matrix type network 
at the site of bleeding, thereby activating the coagulation pathway to provide a 
platform for platelet aggregation and clot formation. At the same time, these agents 
will be ineffective if used on patients with known coagulopathies due to factor 
deficiencies or platelet dysfunction. These products include gelatins, collagens, 
cellulose, and polysaccharide spheres. They require no special storage, minimal or 
no preparation, and are relatively inexpensive [23, 24].
Active hemostatic agents act biologically and directly participate in the coagula-
tion cascade to stimulate fibrinogen at the site of bleeding to produce a fibrin clot 
[21, 25]. These agents primarily include the different forms of thrombin, and are 
useful in patients with coagulopathies or platelet dysfunction [18, 26]. However, 
they rely on the presence of fibrinogen in the patient’s blood to be effective. In 
general, they control bleeding more effectively than passive agents, are more costly, 
and are prepared/available in various forms and formulations.
Flowable hemostatic agents consist of various combinations of active and passive 
components within a single application [20, 27]. This category includes products 
that work by providing a physical barrier to blood flow while actively converting 
fibrinogen in blood into fibrin at the bleeding site [26, 28]. Finally, sealants work by 
the formation of a barrier impervious to flow [24, 29]. There are several types of seal-
ants currently available for use. Our subsequent discussion will focus on each of the 
various types of biosurgicals utilized, with emphasis on neurosurgical applications.
4. Passive hemostatic agents
4.1 Microfibrillar collagen
This material contains 1-μm microcrystals of purified bovine dermal collagen 
available as flour-like or sheet-like format [30, 31]. The microcrystalline collagenous 
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network provides surface for platelets to aggregate while coagulation factors are 
released [30, 31]. The effectiveness of microfibrillar materials may be decreased 
in cases of severe thrombocytopenia (<10,000 mL) [32]. The material should be 
kept dry prior to use because moisture may decrease its activity and the hydro-
philic nature of product results in adherence to surgical gloves and possible mis-
application. Consequently, the material is best handled with sterile forceps. As with 
other biologic hemostats, optimally the smallest amount required to arrest bleeding 
should be utilized, although this may not be precisely known in every situation.
Of importance, microfibrillar collagen is considered a foreign substance and can 
therefore serve as a nidus for infection and/or foreign body reaction [33]. The small 
particles of the flour-like material are useful for arresting bleeding from cancellous 
bone. In this setting, it has demonstrated superior efficacy when compared with 
other agents, such as thrombin alone or thrombin combined with gelfoam [7]. It 
also does not seem to interfere with bone healing in contrast to oxidized cellulose or 
bone wax [34]. It is recommended to firmly pack product into bone surface followed 
by direct pressure for 5–10 minutes. In terms of clinical application considerations, 
it should not be used in areas where it may exert pressure on adjacent structures 
because of fluid absorption and expansion. Also, excessive expansion along a dural 
sinus may lead to occlusion after bone flap replacement. Although collagen is rela-
tively less antigenic and only results in minor inflammation there remains the very 
small risk of allergic reactions [35, 36]. Finally, it can also lead to infection, abscess, 
pseudo-abscess or granuloma formation [37–39].
4.2 Oxidized regenerated cellulose
This type of biomaterial was developed in the 1940’s to help facilitate hemostasis 
[40, 41]. It is available as pads, strips or powder [40, 42, 43]. It can absorb seven to 
ten times its own weight [44]. This ubiquitous hemostatic agent is one of the most 
frequently used. Upon contact with blood, the material reacts to form a reddish 
black gelatinous mass containing hematin (accounts for the color change) [45]. The 
oxidation of cellulose results in a product of low pH with resultant bacteriostatic 
properties [46, 47]. Despite the antimicrobial properties the rates of infection do 
appear to correlate with the amount of retained product [48]. Consequently, though 
often left in place in surgical beds, excess amounts should be removed prior to 
wound closure. Of note, the addition of saline or thrombin to oxidized regenerated 
cellulose may decrease its effectiveness in addition to inactivating thrombin as a 
result of the acidic environment [49]. It may also interfere with bone healing and 
may cause blood vessel compression [49]. Finally, there are reports of excessive 
postoperative swelling of this type of biomaterial [50].
4.3 Absorbable gelatin sponge
Also introduced in the 1940’s this type of hemostatic material consists of water-
insoluble sponges prepared from purified porcine skin gelatin [11]. It provides 
hemostasis by absorbing up to 45x its weight in fluid, thus restricting blood flow 
and providing stable matrix for clot formation [51]. Gelfoam with gentle pressure 
can tamponade and treat most dural sinus bleeding without occlusion of the sinus. 
Although hemostatically beneficial, this capacity to expand physically can lead to 
compression of neural (and vascular) structures [52]. Absorbable gelatin mate-
rial is considered relatively nonreactive, however there have been case reports of 
giant-cell granuloma formation at the implantation site [53, 54]. Although generally 
non-antigenic, this type of biosurgical material is considered a foreign body and 
can serve as a nidus for infection [55].
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4.4 Polysaccharide hemospheres
This is a relatively new category of biosurgicals, derived from vegetable starch 
containing no animal or human components [56–58]. It is available in powder form 
with a bellows-type applicator [56, 59]. The material requires no mixing and is 
available for immediate use. It produces a hydrophilic effect to dehydrate blood and 
concentrate solid components to increase barrier formation [59, 60]. It poses little 
risk to patients since it lacks any human or animal components and should not be 
used in closed spaces because of physical expansion / swelling.
5. Active hemostatic agents
5.1 Thrombin (bovine, pooled human plasma thrombin, and recombinant)
There are three forms of thrombin products differentiated based on type of 
plasma used to provide concentrated thrombin to rapidly convert fibrinogen to 
fibrin clot [61–63]. This class of biosurgicals should be used in cases of mild to 
moderate bleeding, mainly because such products tend to be easily washed off in 
the setting of brisk arterial bleeding or surgical irrigation [64]. In addition, throm-
bin-based hemostatic agents may be less effective in situations of severe fibrinogen 
deficiency [15]. Finally, thrombin products should not be allowed to enter the 
vascular system as intravascular thrombosis can occur [65].
Antibody formation represents a risk with the use of bovine thrombin, leading 
to coagulopathy and even death in rare cases [66, 67]. In fact, there is a “Black Box” 
warning associated with this complication. The use of bovine thrombin is contrain-
dicated if the patient is allergic or has known sensitives to materials of bovine origin 
[23, 68]. On the other hand, pooled human plasma carries a potential risk of viral or 
prion disease transmission since multiple units of blood are required to manufac-
ture each lot of product [69, 70].
5.2 Flowable agents
These products represent a combination of absorbable passive and active 
hemostatic components [71, 72]. One of the flowables currently available is a 
combination of bovine gelatin particles and pooled human thrombin [73, 74], while 
the other consist of absorbable porcine gelatin particles combined with stand-alone 
thrombin [27, 75]. In order to become effective, the flowables require direct contact 
with blood as fibrinogen source [76]. Reconstitution is required, with these prod-
ucts having a paste-like consistency and the ability to “remain in place” compared 
to liquid thrombin [43]. Flowables are applied with a syringe-like applicator and 
require 2–3 minutes of preparation time [28, 77]. Direct injection into emissary 
veins or venous sinuses should be avoided to decrease the risk of dural venous sinus 
thrombosis and post-operative venous stroke.
6. Sealants
6.1 Fibrin sealants/glue
This group of agents consists of concentrated fibrinogen and thrombin. They 
increase the rate of blood clot formation by providing higher concentrations of both 
fibrinogen and thrombin [78]. There are three available types: (a) Pooled human 
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plasma [79, 80]; (b) Individual human plasma, bovine collagen, and bovine throm-
bin [81]; and (c) Pooled human plasma and equine collagen [82].
Sealants may be used in coagulopathic patients with insufficient fibrinogen [64, 
78, 83]. These agents can also be used in heparinized patients since they do not rely 
on host factors for hemostasis [84–86]. Typical indications are hemostasis during 
cardiopulmonary bypass, splenic injuries, and a number of less commonly utilized 
general surgical applications [23]. However, they are widely used as hemostatic 
adjuncts and sealants during neurosurgical procedures, including the prevention of 
cerebrospinal fluid (CSF) leaks [87, 88].
6.2 Polyethylene glycol polymers
There are three different product types in this class of biosurgicals [89, 90]. 
They tend to be most efficacious when used on a relatively dry field to allow 
sufficient time for polymerization [91]. One type of polyethylene glycol polymers 
(PGPs) consists of a combination of 2 polyethylene glycol (PEG) polymers that 
cross-link to each other and contact tissue following application [92]. In effect, 
the PGP-based network acts as a sealant to tissue fluids as well as barrier to cell 
ingrowth and adhesion formation [92, 93].
Another type of PGP material consists of a combination of PEG polymer, 
trilysine amine, and blue dye [94, 95]. This particular component mix produces a 
hydrogel able to help with dural closure because of its ability to form a watertight 
seal [96]. A modified derivative using a reduced molecular weight PEG component 
can be used in sutured dural repair during spinal surgery [96, 97]. The built-in 
blue dye is used to provide accurate placement of sealant [98, 99]. Some concerns 
about this particular material being associated with cases of postoperative spinal 
cord compression have been voiced [94, 100–102]. As such, specific non-expanding 
formulations exist for usage in the spinal canal [103].
The third class of PEG polymer compound consists of a combination with 
human serum albumin. This substance is biodegradable and fairly well studied in 
terms of safety and effectiveness [104]. It provides a strong barrier, as evidenced 
by the FDA approval for use on visceral pleura to close air leaks of >2 mm during 
pulmonary surgeries [105]. There may also be associated economic benefits of using 
this type of biologic sealant [106].
7. Neurosurgical applications
It is important to realize that biosurgical agents are adjuncts to hemostasis 
when standard methods like direct pressure, suturing, or cautery are impractical 
or ineffective [107, 108]. Good knowledge of the mechanism of action of dif-
ferent available biosurgical hemostats is critical, with multiple considerations 
including the patient’s anticoagulation status, the rate of bleeding, the presence 
of thrombocytopenia, fibrinogen level assessment, and many other factors. 
The choice of a specific biosurgical product should be dependent on the type of 
surgery, site of bleeding, other anatomic considerations, cost, and preference of 
the operating neurosurgeon [3, 16, 32, 109, 110].
The continuous oozing encountered from dilated varicose intraspinal veins and 
bone during spinal surgery can be effectively managed with topical hemostats  
[111, 112]. With that said, such materials should not be left in contact with intra or 
extradural nerve roots due to possibility of granuloma formation [39, 53, 54, 113]. 
There have been reports of paraplegia from use of oxidized cellulose during thoracot-
omy from passage of material through the intervertebral foramen resulting in spinal 
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cord compression [114, 115]. Therefore, it is recommended to use only the minimum 
required amount and any excess material should be removed once adequate  
hemostasis is attained.
Biosurgical materials are increasingly applied during spinal cord surgery to help 
with hemostasis since opportunities for electrocautery use are limited in this setting. 
Bipolar cautery, although more focused than monopolar cautery, can also allow dissi-
pation of heat from the tips inducing thermal injury to vascular and neural structures. 
Fibrin glues are commonly used as hemostatic agents in neurosurgical procedures, 
including the management of epidural, cortical, and dural sinus bleeding [116].
During surgical resection of brain tumors, from craniotomy to extradural hemo-
stasis following dural closure, one will find that these agents are generally used 
throughout the procedure. For example, oxidized regenerated cellulose is widely 
used during ablation of lesion(s) and at the end to prevent and abate any bleeding 
in the remaining cavity. However, excess agent should not be left along the surgi-
cal cavity. A single layer of oxidized regenerated cellulose should be sufficient for 
hemostasis without significant risk. Evaluations of the efficacy and safety of poly-
saccharide hemospheres reported no adverse events after use in brain surgery. There 
have been several reports of signal anomalies on post-operative imaging mimicking 
residual tumor or early recurrence, or even abscess when oxidized regenerated 
cellulose or gelatin sponges are left in the operative field. A pediatric case series of 
3 patients who underwent intracerebral surgery with use of microfibrillar collagen 
reported that all required second surgery for new or recurrent seizures [38]. An 
MRI of preoperatively suspected tumor recurrence or abscess subsequently con-
firmed to be microfibrillar collagen-centric necrotizing granuloma surrounded with 
macrophages and eosinophils. One must remain aware of the above considerations 
and remove any local hemostatic agent prior to dural closure.
Bleeding during surgery on the pituitary via a transsphenoidal approach may 
significantly impede visualization while not being conducive of the use of electro-
cautery [117]. The use of oxidized cellulose and Floseal (Baxter, Deerfield, IL) can 
be useful in this situation. Mild persistent oozing from brain tissue following exci-
sion can be controlled with application of oxidized regenerated cellulose followed 
by its removal from the remaining cavity prior to closure. Defects of the skull base 
in some cases require filling of the defect with bone graft, followed by suture and/or 
grafting of the dura reinforced with fibrin sealant. A minimally invasive treatment 
of spontaneous supratentorial intracerebral hemorrhage was also described using 
Floseal. Floseal was placed in 31 patients without evidence of vascular anomalies 
or coagulopathy following evacuation of hematoma from a 3 cm craniotomy. 
Hemostasis was achieved in all but 1 patient who required re-exploration [118].
A multicenter, prospective randomized study with 237 patients undergo-
ing elective cranial surgery demonstrated PEG hydrogel (DuraSeal, Integra 
LifeSciences, Princeton, NJ) similarly safe when used with common dural sealing 
techniques (eg, sutures, autologous grafts, gelatin or collagen sponges, fibrin 
glues) or when used as dural closure augmentation in cranial surgery [99]. The 
incidences of neurosurgical complications, surgical site infections and CSF leaks 
were similar between treatment groups using PEG hydrogel and the control group 
using standard dural sealing techniques. DuralSeal was also found to be statisti-
cally significantly superior to fibrin sealant at preventing CSF leaks following 
posterior fossa craniotomy or craniectomy [119]. However, the special formulation 
of DuraSeal Exact should be used in areas where expansion can lead to neurologic 
compromise – such as the spinal canal [120]. This is because neurologic compro-
mise after expansion has been described in the literature [101, 121]. This again 
emphasizes mindfulness to use to least amount of material to achieve closure and/
or hemostasis while precluding migration or expansion of any excess materials.
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8. Synthesis
Hemostasis in neurosurgery – more so that many other surgical disciplines –  
is challenged by the closed space environment of the brain, spinal cord, and 
other critical structures [3, 122, 123]. Unlike other areas in which the “bulk” 
or space-occupying characteristics of biosurgicals may represent a potential 
benefit as they expand, this is less desirable in neurosurgical applications. In 
the closed environment of the skull, brain, or the spinal cord – even if bone is 
removed to help minimize the effect of swelling from edema – a relatively small 
amount of compression, especially in critical areas, like the brain stem, can have 
devastating consequences. As discussed in previous sections of this chapter, such 
compressive complications, if left untreated can result in irreversible neurologic 
damage [94, 100–102], with resultant “Black Box” warnings clearly outlining 
biomaterial-specific restrictions.
Of growing concern in all aspects of surgery is the increasing utilization of 
anticoagulants and anti-platelet therapies – and often various combinations of both 
[124, 125]. While the indications for such therapies are outside of the scope of this 
review, it is clear that more and more patients are being prescribed agents belong-
ing to these broad medication classes. This is of special significance in the elderly 
population, where anticoagulants and antiplatelet drugs are used for stroke reduc-
tion (e.g., in non-valvular atrial fibrillation); various prophylaxis indications (e.g., 
orthopedic surgery); and of most concern, being used without any clear indications 
[126]. However, many clinical factors that prompt physicians to initiate antiplatelet 
or anticoagulant use also increase the neurosurgical risk associated with even minor 
traumatic events (e.g., falls and minor head injuries). Under such circumstances, 
even minor neurological injuries can quickly evolve into bleeding-related catastro-
phes when patients are anticoagulated [127–129].
Neurosurgical interventions in the setting of traumatic (or even spontaneous) 
subdural, epidural, and intraventricular hemorrhage, when confounded by drugs 
that inherently interfere with hemostasis can compound the difficulties and risks of 
an already complex clinical scenario [130, 131]. The overall challenge can be magni-
fied even further as acute reversal agents tend to be expensive, may not always be 
available, reliable/effective, and could result in thrombotic complications in high-
risk scenarios such as multi-trauma or massive transfusion [131–134]. Furthermore, 
reversal algorithms and guidelines, while helpful do not always definitively address 
the acute problem once significant bleeding starts, and regardless of the mechanism 
and defect in the clotting cascade, a consumptive process may be triggered that 
might require a multi-faceted approach to effectively and timely manage the associ-
ated coagulopathy [134–137]. Similar to other surgical scenarios, such as major 
trauma and cardiothoracic surgery, at times the best way of managing bleeding is 
via a timely and aggressive operative intervention. The above concepts are critical 
in the setting of neurosurgical applications of biosurgical hemostats in that it must 
be recognized that “bleeding” is a complex problem and often requires a combina-
tion of tools to control. Such basic tools require an understanding of the primary 
question – why is this patient bleeding?
• Mechanical bleeding – Direct blood vessel injury that requires sutures, clips, 
and/or physical closure. No amount of blood products, biosurgicals, or other  
hemostatic agents can substitute for definitive surgical hemostasis [138].
• Diffuse oozing – This includes needle holes, micro-circulation (arterial and 
venous), that might benefit from biosurgical agents to augment the natural 
clotting and hemostatic process [138].
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• Defects in the clotting cascade – either physiologic, such as inherent factor 
deficiencies (hemophilia), secondary to pathologic conditions (renal failure, 
acquired Von Willebrand’s disease in aortic stenosis), or iatrogenic from medi-
cal therapies such at anti-coagulants and anti-platelet agents. Even the act of 
surgical incisions and minor tissue trauma can activate various components of 
the clotting cascade and thus complicate bleeding management [138, 139].
• Temperature management – Clotting is a complex enzymatic process that 
has evolved to be optimal at physiologic temperatures. Hypothermia, either 
environmental after trauma, perioperative, or therapeutic (for witnessed 
cardiac arrests, for example) can have potential adverse effects on hemostasis 
and must be considered in the context of a bleeding patient [108, 138, 139].
• Other patient factors and comorbidities can have unpredictable effects on 
hemostasis, but must be considered in the bleeding neurosurgical patients. 
Elderly, debilitated, and frail patients might be malnourished and hence have 
impaired protein stores which contribute to diminished clotting factor reserves 
– even in the setting of normal clotting tests. Patients might be taking herbal 
supplements (which might not even be reported in a medical record or medica-
tion lists) that have been correlated with bleeding risks [140–142].
Each of the above considerations requires a focused approach and highly specific 
management strategy. It is important to recognize that good surgical technique 
must be augmented with a broader understanding of the biologic mechanisms that 
contribute to the overall disease process and that there is no single tool that is ideal 
for all circumstances [108, 138]. Conversely, it must be recognized that there is a 
growing concern that using the wrong or inappropriate therapy for a given clinical 
scenario can be just as problematic, if not intrinsically ineffective or potentially 
dangerous. More so than ever in the past, optimal management of the neurosurgical 
patient (especially one who is bleeding) requires an in-depth and comprehensive 
understanding of the complex mechanisms of hemostasis pathways and the clotting 
cascade while also recognizing those variables, such as pharmaceutical therapies, 
that might adversely impact the normal balance between clotting and bleeding.
In summary, in the setting of neurosurgical bleeding management, several key 
concepts must be recognized:
• Use the right tool for the right job
• Sometimes more than one approach is necessary to control bleeding
• Different types of bleeding might require different management strategies
 ○ Difficult to access areas
 ○ Risk for post-operative re-bleeding
 ○ Compressive or expanding agents can cause devastating complications
 ○ Recognizing the differences between arterial and venous bleeding and how 
management of each might be different
• Understanding the specific reasons why bleeding is occurring and what 
interventions – such as biosurgical agents – should be central to the overall 
hemostatic management.
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• Sometimes the best approach to managing bleeding is preventing it in the first 
place with strict attention to surgical technique and anatomy. It might sound 
inherently obvious, but the best way to avoid a dural sinus bleeding is to avoid 
injury in the first place.
9. Conclusions
Uncontrolled or difficult to control bleeding in neurosurgery is a challenging clini-
cal problem and one that is becoming more common with wider use of anti-coagulant 
and anti-platelet agents in a population that is aging, becoming more frail, has more 
co-morbidities, and is at increasingly greater risk for neurotrauma. In addition, as 
more patients are undergoing major surgical interventions and re-interventions for 
complex neuro-axial pathologies the risks for bleeding complications also increase. 
Effective management of bleeding and bleeding related morbidity requires a thor-
ough understanding of the mechanisms of bleeding and potential biologic defects 
in the normal hemostatic process. With such an understanding, management can be 
more focused and targeted towards the specific problem. Hence, an understanding 
of the adjuvant therapies, such as the full-spectrum of biosurgical agents that can be 
used to manage bleeding is imperative in achieving optimal patient outcomes.
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